These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering. The report provides insights into Bayer AG's tech activities, including its digital ...

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its ...

Bayer pharma chief sees no big acquisitions in near ... and potentially the rise of novel legal theories applied to less traditional products. Here are some of the top cases to watch in 2025.

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...

In a bold move to restore $540 million in cost savings, Bayer CEO Bill Anderson cut out ... teams with a clearer focused on our customers and products,” Hayes shares. Anderson’s push for ...

Meanwhile, Bayer's Pharmaceutical division has delivered ... This growth was driven by significant gains from new products, with Nubeqa and Kerendia achieving growth rates of 83.2% and 96.4% ...

The Ministry of Planning and Investment, the Ministry of Foreign Affairs, and FPT Corporation co-hosted a working breakfast in Davos, Switzerland on January 22 to discuss the future and opportunities ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter. Total revenues ...